Torrent Pharmaceuticals Acquires Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR

Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation

February 7, 2025

Pharmaceuticals

Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) in a carve-out from Mitsubishi Chemical Group Corporation for approximately 510 billion JPY (about $3.3 billion). The deal, led by Bain’s Private Equity teams in Asia and North America together with its Life Sciences group, will create an independent, standalone Japanese pharma platform focused on drug discovery and development across immunology, CNS, vaccines, diabetes and other priority areas; the transaction is expected to close in Q3 2025.

KKR Acquires Bushu Pharmaceuticals from BPEA EQT

December 20, 2022

Pharmaceuticals

KKR has agreed to acquire Bushu Pharmaceuticals, a leading Japanese pharmaceutical CDMO headquartered in Kawagoe, from the BPEA V Fund (BPEA EQT). Bushu operates four manufacturing facilities across Japan, employs around 1,600 people, and provides contract development and manufacturing services for pharmaceuticals and medical devices; the deal is expected to close in Q1 2023 subject to customary approvals.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Jabil Acquires Pharmaceutics International (Pii)

February 6, 2025

Pharmaceuticals

Jabil has acquired Pharmaceutics International (Pii), a Hunt Valley, Maryland-based contract development and manufacturing organization (CDMO) that provides aseptic filling, lyophilization and oral solid dose manufacturing. The all-cash transaction represents an exit for a consortium led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc., and brings Pii’s ~300+ employees and four-site campus into Jabil’s Pharmaceutical Solutions offering to expand its drug development and manufacturing capabilities.

Bayer Acquires UK Biotech KaNDy Therapeutics Ltd.

August 11, 2020

Biotechnology

Bayer has agreed to acquire UK-based clinical-stage biotech KaNDy Therapeutics Ltd. for an upfront $425 million with up to $450 million in additional milestone payments, expanding Bayer's women's healthcare drug development pipeline—specifically the investigational non-hormonal compound NT-814 for menopausal vasomotor symptoms. The acquisition, subject to customary conditions, was announced in August 2020 and is expected to close in September 2020.

ZS Acquires Torrent Consulting to Bolster Salesforce Healthcare and Life Sciences AI Capabilities

December 8, 2025

Healthcare Services

ZS has acquired Torrent Consulting, a Salesforce consulting partner specializing in Health Cloud, Life Sciences Cloud and Agentforce, to strengthen ZS's healthcare, data and AI capabilities and accelerate CRM transformation for healthcare and life sciences clients. The deal brings Salesforce architecture, accelerators and disciplined delivery capabilities into ZS, enabling expanded AI-driven engagement across commercial, medical, service and contact center workflows.